医学
狼疮性肾炎
肾功能受损
增加物
肾炎
系统性红斑狼疮
内科学
免疫学
肾功能
疾病
收益
会计
业务
作者
Mariele Gatto,Giulia Frontini,Claudia Furlan,Marta Calatroni,Claudio Cruciani,Francesco Reggiani,Elisa Bellis,Luca Iaccarino,Renato Alberto Sinico,Gabriella Moroni,Andrea Doria
标识
DOI:10.1016/j.ard.2025.02.004
摘要
To assess the minimum effective duration of remission preventing damage accrual (Systemic Lupus International Collaborating Clinics damage index [SDI]) and impaired kidney function (IKF: estimated glomerular filtration rate of <60 mL/min/1.73 m2 for at least 3 months) in active lupus nephritis (LN). Patients with biopsy-proven LN followed up at least twice yearly were enrolled; clinical variables were collected regularly. Sustained clinical remission (sCR) was defined as estimated glomerular filtration rate of >60 mL/min/1.73 m2, proteinuria of <0.5 g/24 h and clinical systemic lupus erythematosus disease activity index of 0 for at least 1 year. Log-linear regression and a time-dependent Cox proportional hazard model were used to assess the minimum duration of sCR capable of preventing SDI increase and IKF development. In total, 293 patients with LN were included (median follow-up: 15.7 [10.4-22.9] years) of whom 84.3% achieved sCR lasting 8.7 (5.4-13.1) years. At last observation, the increase in SDI was higher in patients who never achieved sCR (median: 2 [1-2.5] vs 1 [0-1.5]; P < .001). A minimum duration of 3 years of sCR prevented SDI increase (% change = -41.1%; P = .003). The analysis on IKF involved only patients with the longest follow-up; 224 patients had ≥10 years of observation. Among them, 50 (22.3%) developed IKF. A minimum duration of 3 years of sCR prevented IKF (hazard ratio = 0.10; P < .001). IKF-free survival rate at 10, 20, and 25 years was 87%, 68%, and 40% for patients who never achieved sCR and 99%, 96%, and 91% for patients with at least 3 years of sCR, respectively (P < .001). Three years is the minimum duration of sCR protecting against development of IKF and damage accrual in patients with LN.
科研通智能强力驱动
Strongly Powered by AbleSci AI